Core Insights - CytoMed Therapeutics Limited is focused on developing affordable donor-derived, cell-based allogeneic immunotherapies, targeting the ASEAN region and North Asia with a population exceeding two billion [2][22] - The company reported a reduced net loss of US$1.85 million for the year ended December 31, 2024, a 39% improvement from US$3.03 million in 2023, primarily due to lower operational costs [4][3] - CytoMed is advancing its clinical trials, including the ANGELICA trial, which is the first-in-human CAR T trial using donor-derived gamma delta T cells [9][10] Financial Performance - Topline income for 2024 was US$624,771, an increase from US$588,423 in 2023 [3] - Cash and bank balances decreased to US$3.64 million as of December 31, 2024, down from US$6.58 million in 2023, but are expected to fund operations through at least 2026 [5] - Research expenses rose to US$1.40 million in 2024 from US$1.16 million in 2023, driven by higher clinical trial costs [6] Clinical Developments - The ANGELICA trial, approved in Singapore, began dosing patients in November 2024, focusing on the use of gamma delta T cells for various cancers [9][10] - A Phase II Investigator Initiated Trial in India is set to commence patient recruitment in the second half of 2025, utilizing CytoMed's manufactured cells [11] - The company is also developing iPSC-derived hybrid immune cells for cancer treatment and has received trial approvals for other conditions [14] Corporate Strategy - CytoMed is exploring a joint venture in China to enhance low-cost cell manufacturing and expand its market reach [16] - The acquisition of a licensed cord blood bank in Malaysia aims to support the development of cord blood-derived therapeutics for autoimmune diseases and cancers [17] - The company plans to establish a liaison office in New York to strengthen its presence in the U.S. market and explore strategic partnerships [19] Future Outlook - An important milestone for 2025 includes the initial clinical readout of the ANGELICA trial and the submission of a U.S. FDA IND application for gamma delta T cells [18] - The company aims to implement alternative revenue-generating methods to assist late-stage patients and capitalize on the growing medical tourism market in Asia [20] - Financial prudence is emphasized, with plans to strengthen financials and prepare for potential mergers and acquisitions in 2025 [21]

Core Insights - CytoMed Therapeutics Limited is focusing on the development of affordable GMP-grade immune cells for patients with cancer and autoimmune diseases, leveraging Asia's low-cost infrastructure and talent [3][4] - The company has achieved significant milestones in 2024, including becoming a clinical stage biopharma and initiating the ANGELICA trial, which is the first-in-human CAR T trial using donor-derived allogeneic gamma delta T cells [4][10] - CytoMed has made strategic acquisitions and partnerships to expand its capabilities and market reach, including the acquisition of a licensed cord blood bank and collaborations in China and India [5][6] Company Developments - The ANGELICA trial commenced in November 2024, with a focus on late-stage cancer patients, supported by a grant from the National Medical Research Council of Singapore [4] - The acquisition of a cord blood bank for approximately US$ 450,000 aims to facilitate the development of cord blood-derived therapeutics, particularly for autoimmune diseases [5] - The company is establishing a presence in New York to enhance its profile in the US market and explore opportunities for mergers and acquisitions [10] Strategic Direction - CytoMed plans to implement revenue-generating methods for late-stage patients, including partnerships with clinics and hospitals in Asia [11] - The company is working towards submitting a US FDA IND for its allogeneic gamma delta T cells and aims for initial clinical readouts from the ANGELICA trial by mid-2025 [10] - The focus on international medical tourism in Asia presents opportunities for developing cell therapies that are often expensive or inaccessible in Western markets [11]

Core Insights - CytoMed Therapeutics Limited is focusing on the development of affordable GMP-grade immune cells for patients with cancer and autoimmune diseases, leveraging Asia's low-cost infrastructure and talent [3][4] - The company has transitioned to a clinical stage biopharma with the initiation of the ANGELICA trial, which is the first-in-human CAR T trial using donor-derived allogeneic gamma delta T cells [4][10] - CytoMed has made strategic acquisitions and partnerships to enhance its capabilities and expand into new markets, including the acquisition of a licensed cord blood bank and collaborations in China and India [5][6] Company Developments - The ANGELICA trial commenced in November 2024, with a small patient recruitment target of no more than 20 late-stage cancer patients, supported by a significant grant from the National Medical Research Council of Singapore [4] - The acquisition of a cord blood bank for approximately US$ 450,000 aims to provide raw materials for new cord blood-derived therapeutics, with plans to spin off this subsidiary in the future [5] - CytoMed is establishing a presence in New York to enhance its profile in the US market and explore opportunities for mergers and acquisitions [10] Strategic Direction - The company plans to implement revenue-generating methods for late-stage patients on a compassionate basis, including investments in clinics and partnerships with hospitals [11] - CytoMed is working towards submitting a US FDA IND for its allogeneic gamma delta T cells and aims for initial clinical readout of the ANGELICA trial by mid-2025 [10] - The company is also involved in an international AI project to utilize its gamma delta T cells for treating infectious diseases in developing countries [9]

Exhibit 99.1 CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS INDEX | Page | | | --- | --- | | Unaudited Interim Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Loss for the Six months | | | ended June 30, 2023 and 2024 | 1 | | Unaudited Interim Condensed Consolidated Statements of Financial Positions as of December 31, 2023 and June 30, 2024 | 2 | | Unaudited Interim Condensed Consolidated Statements of Cash Flows for th ...

Core Insights - CytoMed Therapeutics Limited has acquired the license and certain assets of Cellsafe International Sdn Bhd for approximately RM 2.3 million (US$ 490,000), aiming to enhance its capabilities in developing γδ T cell therapies for cancer treatment [4][21] - The company has received a patent for its iPSC-derived hybrid γδ NKT cells technology, which targets both solid and hematological cancers, expanding its intellectual property portfolio [1][9][18] - CytoMed plans to leverage umbilical cord blood as a valuable resource for producing immune T cells, thereby enhancing the therapeutic potential of cord blood banking [2][14][22] Company Developments - The acquisition includes a cord blood banking license, cryopreservation equipment with over 12,000 cord blood units (CBUs), and two real estate properties [13] - CytoMed aims to be a leading player in γδ T cell technology, focusing on producing clinically relevant numbers of GMP-grade γδ T cells from various sources, including adult peripheral blood and iPSCs [14][19] - The company is conducting the ANGELICA Trial, a phase 1 clinical trial in Singapore, focusing on CAR-T therapies [6][7] Technology and Innovation - γδ T cells, which account for 1% to 5% of body T cells, possess innate tumor recognition capabilities and robust cytotoxic activity against various cancer types [5] - The newly granted patent allows for the generation of hybrid γδ NKT cells without gene editing, providing a platform for potential gene editing in the future [9][18] - CytoMed's proprietary technologies are inspired by the clinical success of existing CAR-T therapies, aiming to address limitations in treating solid tumors [19] Strategic Vision - The company intends to seek strategic partners to develop and grow its subsidiary as a specialized umbilical cord blood-derived immune cell bank [21] - CytoMed's management has shown commitment by obtaining board approval to invest up to a 7% stake in the venture, reflecting confidence in the growth potential [8] - The company is positioned to repurpose cryopreserved assets from cord blood banks, changing the traditional business model of cord blood banking [15][22]

PART I [ITEM 3. KEY INFORMATION](index=15&type=section&id=ITEM%203.%20KEY%20INFORMATION) This section details significant investment risks, encompassing financial position, business operations, manufacturing, intellectual property, commercialization, and share ownership [Risk Factors](index=15&type=section&id=D.%20Risk%20Factors) The company faces extensive risks including financial losses, product development dependency, manufacturing complexities, intellectual property reliance, commercialization challenges, and concentrated share ownership - The company is a pre-clinical stage entity with no approved products and a limited operating history since 2018[38](index=38&type=chunk) - Business success is highly dependent on four unapproved product candidates: CTM-N2D, iPSC-gdNKT, CTM-GDT, and CTM-MSC[54](index=54&type=chunk)[66](index=66&type=chunk) - The company heavily relies on three key technology licenses from Accelerate Technologies Pte. Ltd. (ATPL), whose termination would severely impact core product development[165](index=165&type=chunk) - Principal shareholders, officers, and directors beneficially own approximately **70.80%** of outstanding ordinary shares, granting significant control over shareholder matters[238](index=238&type=chunk) Accumulated Losses (S$) | Date | Accumulated Losses (S$) | | :--- | :--- | | Dec 31, 2021 | S$5.07 million | | Dec 31, 2022 | S$8.20 million | | Dec 31, 2023 | S$12.33 million | [ITEM 4. INFORMATION ON THE COMPANY](index=67&type=section&id=ITEM%204.%20INFORMATION%20ON%20THE%20COMPANY) This section provides a comprehensive overview of CytoMed Therapeutics, covering its history, business operations, organizational structure, and properties [History and Development of the Company](index=67&type=section&id=A.%20History%20and%20Development%20of%20the%20Company) CytoMed Therapeutics Limited, incorporated in Singapore in 2018, operates as a holding company with its main business through its Malaysian subsidiary - The company was incorporated in Singapore on March 9, 2018, converting to a public limited company on January 19, 2023[304](index=304&type=chunk) - A **1-for-380.83** reverse split of its ordinary shares became effective on January 17, 2023[306](index=306&type=chunk) [Business Overview](index=68&type=section&id=B.%20Business%20Overview) CytoMed develops 'off-the-shelf' cell-based immunotherapies using proprietary platforms, with its lead candidate CTM-N2D entering Phase I clinical trials - The company develops 'off-the-shelf' cell-based immunotherapies using healthy donor blood cells and induced pluripotent stem cell (iPSC) technologies[310](index=310&type=chunk)[311](index=311&type=chunk) - The lead product, CTM-N2D, is being evaluated in the ANGELICA Trial, a Phase I study assessing its safety in human subjects[311](index=311&type=chunk)[312](index=312&type=chunk) - The company operates its own cGMP facility in Johor, Malaysia, capable of manufacturing products for Phase I and II clinical trials after NPRA audit[319](index=319&type=chunk)[328](index=328&type=chunk) Product Pipeline and Development Stage | PRODUCT CANDIDATE | INDICATION | STAGE OF DEVELOPMENT | NEXT ANTICIPATED MILESTONES | | :--- | :--- | :--- | :--- | | **CTM-N2D** | R/R SOLID TUMORS | PHASE I | Patient Recruitment 2Q 2024 | | **iPSC-gdNKT** | R/R SOLID TUMORS | DISCOVERY & PROCESS DEVELOPMENT | Preclinical Studies After 2024 | | **CTM-GDT** | R/R SOLID TUMORS | PRECLINICAL STUDIES & TRIAL APPLICATION | IND/CTX Application After 2023 | | **CTM-MSC** | Cartilage Injury | PRECLINICAL STUDIES | Preclinical Studies in Progress | [Organizational Structure](index=128&type=section&id=C.%20Organizational%20Structure) The company is a Singapore-based holding company, conducting primary business operations through its wholly-owned Malaysian subsidiary - CytoMed Therapeutics Limited is a Singapore-based holding company, with main business activities managed by its wholly-owned Malaysian subsidiary, CytoMed Malaysia[598](index=598&type=chunk) [Property, Plants and Equipment](index=128&type=section&id=D.%20Property%2C%20Plants%20and%20Equipment) The company owns a Singapore leasehold for its office and R&D lab, and a freehold cGMP facility in Johor, Malaysia - The company owns the leasehold for its Singapore office and R&D lab at 1 Commonwealth Lane, valid until March 1, 2038[428](index=428&type=chunk) - The company owns a freehold, three-story cGMP facility in Johor, Malaysia, with approximately **8,600 square feet** of gross floor area[432](index=432&type=chunk)[434](index=434&type=chunk) [ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS](index=128&type=section&id=ITEM%205.%20OPERATING%20AND%20FINANCIAL%20REVIEW%20AND%20PROSPECTS) This section analyzes the company's financial performance, highlighting increasing net losses, IPO-supported liquidity, cash flows, and funding requirements [Operating Results](index=128&type=section&id=A.%20Operating%20Results) The company reported no revenue from 2021-2023, with net loss increasing to S$4.13 million in 2023 due to higher IPO and public company expenses - The company, a pre-clinical stage entity, has not generated any revenue from product sales since its inception[606](index=606&type=chunk)[608](index=608&type=chunk) - Other expenses surged to **S$2.21 million** in 2023 from **S$0.49 million** in 2022, primarily due to offering and public company costs[620](index=620&type=chunk) - Research income, from manufacturing cells for researchers on a cost-recovery basis, increased by **39.5%** in 2023 to **S$507,736**[609](index=609&type=chunk)[611](index=611&type=chunk) Consolidated Statement of Profit or Loss (S$) | | 2021 | 2022 | 2023 | | :--- | :--- | :--- | :--- | | **Revenue** | - | - | - | | **Other operating income** | 154,610 | 485,374 | 803,904 | | **Research expenses** | (1,090,623) | (1,522,765) | (1,589,693) | | **Other expenses** | (518,766) | (494,675) | (2,213,142) | | **Loss for the year** | **(2,051,903)** | **(3,131,452)** | **(4,133,170)** | [Liquidity and Capital Resources](index=135&type=section&id=B.%20Liquidity%20and%20Capital%20Resources) The company's liquidity is primarily funded by its S$10.31 million IPO proceeds, with cash and equivalents increasing to S$9.00 million by year-end 2023 - The company's IPO on April 18, 2023, raised net proceeds of approximately **S$10.31 million** (**U.S.$7.81 million**)[604](index=604&type=chunk) Cash and Cash Equivalents & Accumulated Losses (S$) | As of December 31 | 2021 | 2022 | 2023 | | :--- | :--- | :--- | :--- | | **Cash and cash equivalents** | S$2.51 million | S$1.58 million | S$9.00 million | | **Accumulated losses** | S$5.07 million | S$8.20 million | S$12.33 million | Summary of Cash Flows (S$) | For the year ended Dec 31 | 2021 | 2022 | 2023 | | :--- | :--- | :--- | :--- | | **Net cash used in operating activities** | (1,712,985) | (1,398,409) | (3,432,830) | | **Net cash used in investing activities** | (823,666) | (473,305) | (2,829,175) | | **Net cash generated from financing activities** | 4,173,396 | 968,716 | 10,919,885 | [ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES](index=141&type=section&id=ITEM%206.%20DIRECTORS%2C%20SENIOR%20MANAGEMENT%20AND%20EMPLOYEES) This section details the company's leadership, compensation practices, board structure, and employee base, including its 34 full-time employees [Directors and Senior Management](index=141&type=section&id=A.%20Directors%20and%20Senior%20Management) The company's leadership comprises a nine-member Board of Directors, including four executive and five independent directors, along with key executive officers - The Board of Directors comprises **9** members: **4** executive directors and **5** independent directors[664](index=664&type=chunk)[699](index=699&type=chunk) [Compensation](index=148&type=section&id=B.%20Compensation) This subsection details 2023 compensation for Named Executive Officers and non-employee directors, including annual cash retainers and the adoption of a Clawback Policy - Non-employee directors receive annual cash retainers for Board service (**U.S.$12,000**) and committee service, with additional retainers for chairpersons[697](index=697&type=chunk) 2023 Named Executive Officer Compensation (U.S.$) | Name and Principal Position | Salary (U.S.$) | Bonus (U.S.$) | All Other Compensation (U.S.$) | Total (U.S.$) | | :--- | :--- | :--- | :--- | :--- | | **CHOO Chee Kong**, Chairman | 23,043 | - | 4,273 | 27,316 | | **Dr. ZENG Jieming**, Chief Scientific and Medical Officer | 88,226 | 1,516 | - | 89,742 | | **Dr. TAN Wee Kiat**, Co-CEO and COO | 86,614 | 1,516 | - | 88,130 | [Employees](index=152&type=section&id=D.%20Employees) The company employs 34 full-time staff, with 28 in R&D and manufacturing, and has adopted a 2023 Equity Incentive Plan - The company has **34** full-time employees, with **28** (approximately **82%**) focused on R&D and manufacturing[713](index=713&type=chunk) - The company adopted the 2023 Equity Incentive Plan, making **1,279,117** ordinary shares available for issuance as share options or restricted shares[717](index=717&type=chunk)[718](index=718&type=chunk) [ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS](index=155&type=section&id=ITEM%207.%20MAJOR%20SHAREHOLDERS%20AND%20RELATED%20PARTY%20TRANSACTIONS) This section details the company's ownership structure, including major shareholders, and significant related party transactions [Major Shareholders](index=155&type=section&id=A.%20Major%20Shareholders) The company's ownership is concentrated among a few major shareholders, with Glorious Finance Limited holding **40.33%** and all directors and NEOs owning **33.31%** Beneficial Ownership of Ordinary Shares (%) | Shareholder | Number of Shares | Percentage (%) | | :--- | :--- | :--- | | Glorious Finance Limited | 4,653,604 | 40.33% | | mDR Limited | 1,336,923 | 11.59% | | WANG Shu | 883,858 | 7.66% | | ZENG Jieming | 589,239 | 5.11% | | All directors and NEOs as a group (9 persons) | 3,844,299 | 33.31% | [Related Party Transactions](index=156&type=section&id=B.%20Related%20Party%20Transactions) Significant related party transactions include Chairman CHOO Chee Kong's personal guarantees for loans and the company's investment in Landmark Medical Centre - Chairman CHOO Chee Kong provided a personal guarantee for a **RM2 million** credit facility for the Malaysian subsidiary's cGMP Facility construction[737](index=737&type=chunk) - The company acquired a **20%** equity stake in Landmark Medical Centre Sdn Bhd (LMC), a private hospital where director Dr. Lucas LUK Tien Wee is a shareholder and Medical Director[743](index=743&type=chunk) [ITEM 8. FINANCIAL INFORMATION](index=159&type=section&id=ITEM%208.%20FINANCIAL%20INFORMATION) This section confirms the inclusion of financial statements, absence of significant legal proceedings, and the company's policy of retaining earnings for business expansion - The company has not been subject to any significant legal or arbitration proceedings[753](index=753&type=chunk) - The company does not intend to pay dividends in the near future, planning to retain earnings to finance business expansion[757](index=757&type=chunk) [ITEM 10. ADDITIONAL INFORMATION](index=161&type=section&id=ITEM%2010.%20ADDITIONAL%20INFORMATION) This section covers supplementary corporate information, including material contracts, exchange controls, and detailed taxation considerations for Singapore and U.S. Holders [Taxation](index=161&type=section&id=E.%20Taxation) This subsection details material tax implications for investors in Singapore and the United States, including the risk of PFIC classification for U.S. Holders - Under Singapore's one-tier tax system, dividends paid by the company are tax-exempt for shareholders, regardless of residency[780](index=780&type=chunk) - Singapore does not impose tax on capital gains, though gains from share disposal could be considered income if from trade or business activities[781](index=781&type=chunk) - There is a risk the company could be classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse tax treatment for U.S. Holders[803](index=803&type=chunk)[805](index=805&type=chunk) PART II [ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS](index=168&type=section&id=ITEM%2014.%20MATERIAL%20MODIFICATIONS%20TO%20THE%20RIGHTS%20OF%20SECURITY%20HOLDERS%20AND%20USE%20OF%20PROCEEDS) This section addresses the use of proceeds from the company's IPO, confirming approximately S$10.31 million in net proceeds and no material change in their planned use - The company's Initial Public Offering (IPO) generated net proceeds of approximately **S$10.31 million** (**U.S.$7.81 million**)[824](index=824&type=chunk) - As of December 31, 2023, there has been no material change in the intended use of IPO proceeds as described in the registration statement[825](index=825&type=chunk) [ITEM 15. CONTROLS AND PROCEDURES](index=168&type=section&id=ITEM%2015.%20CONTROLS%20AND%20PROCEDURES) This section discusses the ineffectiveness of the company's disclosure controls and procedures as of December 31, 2023, due to insufficient financial reporting personnel - Management concluded that as of December 31, 2023, the company's disclosure controls and procedures were ineffective[826](index=826&type=chunk) - The ineffectiveness stemmed from insufficient financial reporting and accounting personnel with adequate knowledge of U.S. GAAP and SEC reporting requirements[826](index=826&type=chunk) [ITEM 16. CORPORATE GOVERNANCE AND OTHER DISCLOSURES](index=170&type=section&id=ITEM%2016.%20CORPORATE%20GOVERNANCE%20AND%20OTHER%20DISCLOSURES) This section covers corporate governance, including the Audit Committee Financial Expert, Code of Ethics, accountant fees, home country practices, and controlled company status - The board identified Mark LEONG Kei Wei as the 'Audit Committee Financial Expert'[833](index=833&type=chunk) - As a foreign private issuer, the company follows Singaporean home country practice for shareholder meeting quorum and is exempt from Nasdaq's independent director majority rule[842](index=842&type=chunk) - The company is a 'controlled company' under Nasdaq rules due to principal shareholders, officers, and directors holding a majority of its ordinary shares[843](index=843&type=chunk) Principal Accountant Fees (U.S.$) | Fee Type | 2022 (U.S.$) | 2023 (U.S.$) | | :--- | :--- | :--- | | Audit Fees | 70,000 | 85,000 | | Audit-Related Fees | 18,000 | 20,000 | | Tax Fees | - | - | | All Other Fees | - | - | PART III [ITEM 18. FINANCIAL STATEMENTS](index=173&type=section&id=ITEM%2018.%20FINANCIAL%20STATEMENTS) This section presents the audited consolidated financial statements for CytoMed Therapeutics Limited and its subsidiaries for the three years ended December 31, 2023 [Consolidated Statements of Financial Positions](index=179&type=section&id=Consolidated%20Statements%20of%20Financial%20Positions) Total assets significantly increased to S$12.37 million in 2023, while total liabilities decreased to S$1.12 million, leading to a substantial rise in total equity Consolidated Statements of Financial Positions (S$) | | 2022 | 2023 | | :--- | :--- | :--- | | **Total current assets** | 2,493,862 | 10,096,631 | | **Total non-current assets** | 2,733,196 | 2,272,239 | | **Total assets** | **5,227,058** | **12,368,870** | | **Total current liabilities** | 4,165,224 | 716,943 | | **Total non-current liabilities** | 475,536 | 407,772 | | **Total liabilities** | **4,640,760** | **1,124,715** | | **Total equity** | **586,298** | **11,244,155** | [Consolidated Statements of Profit or Loss and Other Comprehensive Loss](index=180&type=section&id=Consolidated%20Statements%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Loss) The company reported no revenue from 2021-2023, with the annual loss widening to S$4.13 million in 2023 due to increased expenses Consolidated Statements of Profit or Loss and Other Comprehensive Loss (S$) | | 2021 | 2022 | 2023 | | :--- | :--- | :--- | :--- | | **Revenue** | - | - | - | | **Loss before income tax** | (2,051,903) | (3,129,812) | (4,132,517) | | **Loss for the year** | **(2,051,903)** | **(3,131,452)** | **(4,133,170)** | | **Total comprehensive loss for the year** | **(2,074,531)** | **(3,227,956)** | **(4,223,088)** | [Consolidated Statements of Changes in Equity](index=182&type=section&id=Consolidated%20Statements%20of%20Changes%20in%20Equity) Total equity significantly increased to S$11.24 million by end of 2023, primarily driven by S$14.81 million in new share issuances from IPO and loan conversions Consolidated Statements of Changes in Equity (S$) | | Share capital | Accumulated losses | Total equity | | :--- | :--- | :--- | :--- | | **Balance at Dec 31, 2021** | 6,548,960 | (5,067,332) | 2,591,604 | | **Total comprehensive loss for 2022** | - | (3,131,209) | (3,227,956) | | **Issuance of shares in 2022** | 2,364,045 | - | 1,222,650 | | **Balance at Dec 31, 2022** | 8,913,005 | (8,198,541) | 586,298 | | **Total comprehensive loss for 2023** | - | (4,132,896) | (4,223,088) | | **Issuance of shares in 2023** | 14,807,015 | - | 14,807,015 | | **Balance at Dec 31, 2023** | **23,720,020** | **(12,331,437)** | **11,244,155** | [Consolidated Statements of Cash Flows](index=183&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Operating activities used S$3.43 million in cash for 2023, while financing activities provided S$10.92 million, resulting in a net increase in cash and equivalents to S$6.22 million Consolidated Statements of Cash Flows (S$) | | 2021 | 2022 | 2023 | | :--- | :--- | :--- | :--- | | **Net cash used in operating activities** | (1,712,985) | (1,398,409) | (3,432,830) | | **Net cash used in investing activities** | (823,666) | (473,305) | (2,829,175) | | **Net cash from financing activities** | 4,173,396 | 968,716 | 10,919,885 | | **Net increase/(decrease) in cash** | 1,636,745 | (902,998) | 4,657,880 | | **Cash and cash equivalents at end of year** | **2,512,768** | **1,579,718** | **6,224,187** |

SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel blood donor-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has obtained board approval to launch, subject to certain terms and conditions, a pilot program ("Program") to isolate and cryo-store peripheral blood mononuclear cell ...

SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, today announced that it has entered into a Research Collaboration Agreement ("RCA") with Sengkang General Hospital Pte Ltd ("SKH"), a public hospital in Singapore and a membe ...

Financial Performance - As of December 31, 2022, the company reported accumulated losses of S$8.20 million, with net cash used in operating activities amounting to S$1.40 million[631]. - The company had cash and cash equivalents of S$1.58 million as of December 31, 2022, down from S$2.51 million in 2021[632]. - Net cash used in investing activities for 2022 was S$473,305, primarily due to the purchase of property, plant, and equipment[638]. - The company generated S$968,716 from financing activities in 2022, mainly from the issuance of ordinary shares totaling S$1.22 million[641]. Future Outlook - The company expects significant increases in expenses and capital requirements as it continues R&D activities and seeks regulatory approvals for product candidates[631]. - The company plans to fund its operations through various sources, including loans, equity, and debt financings[632]. - The company has contractual obligations totaling S$2.16 million, with S$1.83 million related to convertible bonds due within one year[647]. - The company has not yet commercialized any product candidates and does not expect to generate revenue from commercial sales in the foreseeable future[630]. Research and Development - The company is conducting the ANGELICA Trial with National University Hospital Singapore as part of its ongoing R&D efforts[642]. - The company estimates accrued R&D expenses based on known facts and circumstances, with no material adjustments to prior estimates reported to date[653]. Company Classification - The company is classified as an "emerging growth company" and has opted for delayed adoption of certain accounting standards[659]. - The company will maintain its emerging growth status until it exceeds U.S.$1.235 billion in annual revenue or meets other specified criteria[660]. Shareholder Actions - On April 21, 2023, the mDR Convertible Loan was converted into 589,509 ordinary shares at approximately U.S.$1.89774 per share[661].